Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-041
- Sponsors Merck Sharp & Dohme
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.
- 25 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2016.
- 11 Jul 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2016.